Real World Perspectives on the Role of TYK2 Inhibitors in the Treatment of Psoriasis

Real-World Perspectives on the Role of TYK2 Inhibitors in the Treatment of Psoriasis

Clinical Commentary

How are TYK2 inhibitors different from conventional JAK inhibitors? In what patient population would they be best suited? Find out in this expert-led clinical review and panel discussion that provides the knowledge you need on the investigational TYK2 inhibitors and their potential roles in personalized psoriasis treatment plans. This content is available across two modules, allowing you to choose where to focus your time.

Discussion topics include:

• TYK2 role in psoriasis pathogenesis

• Latest TYK2 inhibitor clinical evidence

• How to differentiate TYK2 inhibitors from conventional JAK inhibitors

• Current psoriasis treatment paradigms

• TYK2 inhibitor potential place in therapy

• Shared decision-making in psoriasis care

Faculty: April Armstrong, MD, MPH; Neal Bhatia, MD; Mark Lebwohl, MD

Release Date: September 30, 2021

Expiration Date: September 30, 2022

CME/CE is no longer available for this activity